Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in Idiopathic Pulmonary Fibrosis
NCT01629667Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Oct 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tralokinumab in idiopathic pulmonary fibrosis (IPF), sponsored by MedImmune. Started Oct 2012; status: terminated.
02
Drugs
tralokinumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01629667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01629667.